Colonization of Bile Ducts and Infectious Complications in Cephalic Duodenopancreatectomy

Sponsor
Central Hospital, Nancy, France (Other)
Overall Status
Completed
CT.gov ID
NCT04555252
Collaborator
(none)
70
1
15.9
4.4

Study Details

Study Description

Brief Summary

Cephalic duodenopancreatectomy is part of the curative treatment for pancreatic cancer of the head and peri-ampullary area. The mortality of the procedure is around 5%, with a morbidity ranging from 30 to 50%. Infectious complications account for 35% of overall morbidity.

One of the risk factors for postoperative complications is the existence of preoperative retentional jaundice, due to tumoral obstruction of the main bile duct In these cases, it is proposed to perform preoperative bile duct drainage, preferably by endoscopic stenting (ERCP).

However, several studies have shown these procedures to cause biliary contamination which could be responsible for an increase in post-operative morbidity such as infectious complications and increased length of stay in hospital..

Thus, the biliary microbial flora is more often multi-microbial and may contain multidrug-resistant nosocomial germs,

The study carried out by Cortes et al., based on a control case study design, also showed that a correlation between biliary colonization and postoperative infectious complications existed in patients who benefited from a preoperative biliary drainage technique. In fact, the bacteria isolated during intraoperative bile sampling were similar, in 49% of cases, to those isolated during bacteriological samples collected postoperatively during infectious complications.

The work carried out by Krüger and al has shown that the spectrum of bacteria found in the preoperative bile samples from patients who have undergone bile duct dilation is potentially not covered by standard antibiotic therapy.

The aim of this observational prospective study is to investigate this correlation between biliary colonization and postoperative infectious complications, to evaluate the morbidity and postoperative mortality of cephalic duodenopancreatectomies performed at the CHRU of Nancy and to study a possible adaptation of perioperative antibiotic prophylaxis.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    70 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Colonization of Bile Ducts and Post-operative Infectious Complications of Cephalic Duodenopancreatectomy : A Prospective Observational Study
    Actual Study Start Date :
    Feb 1, 2020
    Actual Primary Completion Date :
    Mar 28, 2021
    Actual Study Completion Date :
    May 31, 2021

    Arms and Interventions

    Arm Intervention/Treatment
    Cephalic Duodenopancreatectomy

    Patients who underwent scheduled cephalic duodenopancreatectomy and hospitalized in intensive care.

    Outcome Measures

    Primary Outcome Measures

    1. Comparison of preoperative Bile and postoperative infection sites microbiology results [from date of initial bile sample up to 30 days of postoperative period]

      bacterial count in log10 bacteria/ml and identification

    Secondary Outcome Measures

    1. Impact of prior biliary drainage on the intraoperative bile microbiological results bacteriological results obtained [from date of initial bile sampling to date of surgery (up to 90 days)]

      bacterial count in log10 bacteria/ml and species identification

    2. Microbial flora in clinical specimens obtained from different sites [from date of initial bile sample up to 90 postoperative days]

      bacterial count in log10 bacteria/ml and species identification

    3. Non infectious surgical complications using scores [from date of surgery up to 30 postoperative days]

      Clavien-Dindo Classification, SOFA score

    4. postoperative infectious complications as defined by the Centers for Disease Control and Prevention (Atlanta, Ga) [During hospital stay (up to 90 days after surgery)]

      number of event occurence

    5. Implication of bacteria found in biliculture as causative agent in post-operative infections [During hospital stay (up to 90 days after surg]

      incidence in percentage

    6. length of stay in intensive care and hospital [During the ICU stay and hospital]

      Number of days in ICU and hospital

    7. mortality rate [At day +28 and day +90]

      number of death at 28 days and 90 days

    8. Description of nutrition assistance [from date of initial bile sample up to 30 days of postoperative period]

      Parenteral, enteral, oral feeding in days and calories

    9. Nutritional status measured by nutritional risk index (NRI) [preoperative]

      Body mass index (BMI) and albuminemia computation

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age > 18 years

    • Patient operated for a planned cephalic duodenopancreatectomy

    • Post-operative hospitalisation in ICU

    • Information leaflet given to the patient and the support person, with oral information, during the post-operative period

    Exclusion Criteria:
    • Age < 18 years

    • Emergency duodenopancreatectomy (surgical indication period less than 48 hours)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Chru Nancy Vandœuvre-lès-Nancy France 54511

    Sponsors and Collaborators

    • Central Hospital, Nancy, France

    Investigators

    • Principal Investigator: MARIE-REINE LOSSER, MD,PhD, CHRU Nancy

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Central Hospital, Nancy, France
    ClinicalTrials.gov Identifier:
    NCT04555252
    Other Study ID Numbers:
    • CHRU NANCY : 2019PI249
    First Posted:
    Sep 18, 2020
    Last Update Posted:
    Jul 12, 2021
    Last Verified:
    Jul 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Central Hospital, Nancy, France
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 12, 2021